loratadine has been researched along with Asthma in 47 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loratadine added to montelukast has been suggested to improve endpoints of asthma." | 9.14 | A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009) |
| "Ten adults with mild-to-moderate atopic asthma participated in a randomized, 4-way crossover study design comparing placebo, 5 mg of desloratadine, 10 mg of montelukast, and the combination administered at 26 hours and 2 hours before each allergen challenge conducted at least 7 days apart." | 9.11 | Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. ( Cockcroft, DW; Davis, BE; Todd, DC, 2005) |
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 9.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "Asthma symptoms and beta(2)-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily." | 9.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "Loratadine has a mild bronchodilatory effect in the study period and does not interfere with the bronchodilatory effect of terbutaline in childhood asthma." | 9.10 | The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma. ( Baki, A; Orhan, F, 2003) |
| "This 4-week, multicenter, parallel-group, double-blind study evaluated desloratadine treatment (5 mg once daily) versus placebo in 331 subjects with SAR and mild seasonal allergic asthma." | 9.10 | Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002) |
| "Montelukast sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma." | 9.09 | Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 9.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "To evaluate whether loratadine, a selective H1 receptor antagonist, given as an adjunct to standard asthma medication would have any effect in patients with moderate-to-severe asthma." | 9.08 | Lack of effect of loratadine on moderate to severe asthma. ( Ekström, T; Osterman, K; Zetterström, O, 1995) |
| "The results of this study show that loratadine, employed as an adjuvant therapeutic agent for the treatment of allergic bronchial asthma has a positive effect on symptomatology." | 9.07 | [Allergic bronchial asthma treated with Loratadine]. ( Kroll, VM; Nothofer, B; Werdermann, K, 1993) |
| " In a randomized, double-blind, crossover study, we evaluated the effects of loratadine, 10 and 20 mg, and placebo administered once daily for 3 days on the skin-wheal responses to histamine, the airway responses to inhaled histamine and methacholine, and the skin-wheal and airway responses to allergen in 12 subjects with asthma." | 9.06 | Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. ( Holgate, ST; Town, GI, 1990) |
| "Seventeen patients with perennial asthma, stable on a moderate dose of inhaled steroid, participated in a crossover study comparing the clinical effect of a non-sedative, potent and highly selective H1 antagonist (loratadine 10 mg) with placebo." | 9.06 | Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial. ( Dirksen, A; Engel, T; Frølund, L; Heinig, JH; Svendsen, UG; Weeke, B, 1989) |
| "To evaluate the efficacy and safety of loratadine, a new generation of antihistaminics, in the treatment of childhood asthma." | 8.87 | [Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma]. ( Abduhaer, A; Maimaiti, G; Xu, PR, 2011) |
| "We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma." | 7.72 | Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 6.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Loratadine added to montelukast has been suggested to improve endpoints of asthma." | 5.14 | A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009) |
| "Montelukast and desloratadine synergistically inhibit the allergen-induced early asthmatic response." | 5.14 | Single-dose desloratadine and montelukast and allergen-induced late airway responses. ( Boulet, LP; Cockcroft, DW; Davis, BE; Deschesnes, F; Gauvreau, GM; Illamperuma, C; O'Byrne, PM; Watson, RM, 2009) |
| "Ten adults with mild-to-moderate atopic asthma participated in a randomized, 4-way crossover study design comparing placebo, 5 mg of desloratadine, 10 mg of montelukast, and the combination administered at 26 hours and 2 hours before each allergen challenge conducted at least 7 days apart." | 5.11 | Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. ( Cockcroft, DW; Davis, BE; Todd, DC, 2005) |
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 5.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "This 4-week, multicenter, parallel-group, double-blind study evaluated desloratadine treatment (5 mg once daily) versus placebo in 331 subjects with SAR and mild seasonal allergic asthma." | 5.10 | Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002) |
| "Sixteen atopic patients with mild-to-moderate asthma of whom 10 were receiving inhaled corticosteroid therapy (all had positive results to house dust mite on skin prick testing) were randomized in a double-blind, placebo-controlled, cross-over fashion to receive single doses of 5 mg of desloratadine, 180 mg of fexofenadine hydrochloride (FEX), 5 mg of levocetirizine dihydrochloride (LEV), or placebo, with AMP challenge performed 12 hours after dosing." | 5.10 | Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. ( Bates, CE; Currie, GP; Lee, DK; Lipworth, BJ, 2003) |
| "Asthma symptoms and beta(2)-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily." | 5.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "The aim of the study was to evaluate the protective effect of single-dose, combination treatment comprising montelukast (5 mg) and loratadine (10 mg), on exercise-induced bronchoconstriction in asthmatic children." | 5.10 | The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. ( Boner, AL; De Gasperi, W; Loiacono, A; Micciolo, R; Peroni, DG; Piacentini, GL; Pietrobelli, A; Sabbion, A, 2002) |
| "On the basis of low dose inhaled corticosteroid, orally administered Loratadine significantly improves the therapeutic efficacy of asthma in patients with allergic asthma and rhinitis." | 5.10 | [Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis]. ( Cai, DM; He, WQ; Lin, H; Liu, HZ; Ran, PX; Xu, JM; Zheng, JP; Zhong, NS, 2003) |
| "Loratadine has a mild bronchodilatory effect in the study period and does not interfere with the bronchodilatory effect of terbutaline in childhood asthma." | 5.10 | The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma. ( Baki, A; Orhan, F, 2003) |
| "Montelukast sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma." | 5.09 | Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000) |
| "To evaluate whether loratadine, a selective H1 receptor antagonist, given as an adjunct to standard asthma medication would have any effect in patients with moderate-to-severe asthma." | 5.08 | Lack of effect of loratadine on moderate to severe asthma. ( Ekström, T; Osterman, K; Zetterström, O, 1995) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 5.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "Twenty-four adult asthmatic subjects were included in a parallel group study that compared the duration of effect of two antihistamines and a placebo on cutaneous and inhaled reactivity to histamine." | 5.07 | Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Labrecque, M; Malo, JL; Trudeau, C, 1993) |
| "The results of this study show that loratadine, employed as an adjuvant therapeutic agent for the treatment of allergic bronchial asthma has a positive effect on symptomatology." | 5.07 | [Allergic bronchial asthma treated with Loratadine]. ( Kroll, VM; Nothofer, B; Werdermann, K, 1993) |
| " In a randomized, double-blind, crossover study, we evaluated the effects of loratadine, 10 and 20 mg, and placebo administered once daily for 3 days on the skin-wheal responses to histamine, the airway responses to inhaled histamine and methacholine, and the skin-wheal and airway responses to allergen in 12 subjects with asthma." | 5.06 | Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. ( Holgate, ST; Town, GI, 1990) |
| "Seventeen patients with perennial asthma, stable on a moderate dose of inhaled steroid, participated in a crossover study comparing the clinical effect of a non-sedative, potent and highly selective H1 antagonist (loratadine 10 mg) with placebo." | 5.06 | Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial. ( Dirksen, A; Engel, T; Frølund, L; Heinig, JH; Svendsen, UG; Weeke, B, 1989) |
| "To evaluate the efficacy and safety of loratadine, a new generation of antihistaminics, in the treatment of childhood asthma." | 4.87 | [Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma]. ( Abduhaer, A; Maimaiti, G; Xu, PR, 2011) |
| "We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af ) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma." | 3.72 | Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. ( Bryce, PJ; Geha, R; Oettgen, HC, 2003) |
| "The influence of single and repeated LO (10 mg/day) doses on histamine-induced bronchoconstriction was studied in 11 patients with stabile bronchial asthma." | 3.68 | [Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction]. ( Cieślewicz, G; Gondorowicz, K; Grzelewska-Rzymowska, I; Rozniecki, J; Wojciechowska, B, 1992) |
| "Montelukast was not significantly different from placebo." | 2.71 | Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. ( Anderson, SD; Brannan, JD; Currie, GP; Fowler, SJ; Haggart, K; Lee, DK; Lipworth, BJ; Wilson, AM, 2003) |
| "Treatment with montelukast and loratadine inhibited the release of cysteinyl leukotrienes and histamine into the airways, but did not inhibit the release of columnar epithelial cells into the airways." | 2.71 | Inflammatory basis of exercise-induced bronchoconstriction. ( Aitken, ML; Hallstrand, TS; Henderson, WR; Moody, MW; Schwartz, LB; Wurfel, MM, 2005) |
| "Loratadine treatment was not more sedative than placebo and was not associated with cardiovascular events." | 2.71 | Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. ( Adam, D; Bismut, H; Bonini, S; Borres, MP; Canonica, GW; Canseco Gonzalez, C; Czarlewski, W; Danzig, MR; Grimfeld, A; Holgate, ST; Lobaton, P; Patel, P; Roman, I; Szczeklik, A, 2004) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 2.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Triamcinolone is a commonly used synthetic corticosteroid that has recently been tested in a large clinical trial for chronic obstructive pulmonary disease and shown to have some benefits." | 2.41 | Triamcinolone: new and old indications. ( Doggrell, SA, 2001) |
| "Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity." | 1.31 | Desloratadine: A new, nonsedating, oral antihistamine. ( Geha, RS; Meltzer, EO, 2001) |
| " The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers." | 1.31 | Desloratadine. ( Jarvis, B; McClellan, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 13 (27.66) | 18.2507 |
| 2000's | 30 (63.83) | 29.6817 |
| 2010's | 3 (6.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, BE | 2 |
| Illamperuma, C | 1 |
| Gauvreau, GM | 1 |
| Watson, RM | 1 |
| O'Byrne, PM | 1 |
| Deschesnes, F | 1 |
| Boulet, LP | 1 |
| Cockcroft, DW | 2 |
| Ngamphaiboon, J | 1 |
| Wirawarn, T | 1 |
| Thongkaew, T | 1 |
| Lu, S | 1 |
| Liu, N | 1 |
| Dass, SB | 1 |
| Reiss, TF | 1 |
| Wang, Y | 2 |
| Wang, J | 1 |
| Lin, Y | 2 |
| Si-Ma, LF | 1 |
| Wang, DH | 2 |
| Chen, LG | 2 |
| Liu, DK | 1 |
| Maimaiti, G | 1 |
| Abduhaer, A | 1 |
| Xu, PR | 1 |
| Sima, LF | 1 |
| Li, L | 1 |
| Peroni, DG | 1 |
| Piacentini, GL | 1 |
| Pietrobelli, A | 1 |
| Loiacono, A | 1 |
| De Gasperi, W | 1 |
| Sabbion, A | 1 |
| Micciolo, R | 1 |
| Boner, AL | 1 |
| Berger, WE | 2 |
| Schenkel, EJ | 1 |
| Mansfield, LE | 1 |
| Bachert, C | 1 |
| Lee, DK | 2 |
| Bates, CE | 1 |
| Currie, GP | 2 |
| Lipworth, BJ | 2 |
| Baena-Cagnani, CE | 2 |
| DuBuske, LM | 2 |
| Gurné, SE | 1 |
| Stryszak, P | 1 |
| Lorber, R | 1 |
| Danzig, M | 1 |
| Haggart, K | 1 |
| Fowler, SJ | 1 |
| Wilson, AM | 2 |
| Brannan, JD | 1 |
| Anderson, SD | 1 |
| He, WQ | 1 |
| Zheng, JP | 1 |
| Ran, PX | 1 |
| Liu, HZ | 1 |
| Lin, H | 1 |
| Cai, DM | 1 |
| Xu, JM | 1 |
| Zhong, NS | 1 |
| Bryce, PJ | 1 |
| Geha, R | 1 |
| Oettgen, HC | 1 |
| Orhan, F | 1 |
| Baki, A | 1 |
| Magnan, A | 1 |
| Grimfeld, A | 1 |
| Holgate, ST | 3 |
| Canonica, GW | 1 |
| Bonini, S | 1 |
| Borres, MP | 1 |
| Adam, D | 1 |
| Canseco Gonzalez, C | 1 |
| Lobaton, P | 1 |
| Patel, P | 1 |
| Szczeklik, A | 1 |
| Danzig, MR | 1 |
| Roman, I | 1 |
| Bismut, H | 1 |
| Czarlewski, W | 1 |
| Hallstrand, TS | 1 |
| Moody, MW | 1 |
| Wurfel, MM | 1 |
| Schwartz, LB | 1 |
| Henderson, WR | 1 |
| Aitken, ML | 1 |
| Reinartz, SM | 1 |
| Overbeek, SE | 1 |
| Kleinjan, A | 1 |
| van Drunen, CM | 1 |
| Braunstahl, GJ | 1 |
| Hoogsteden, HC | 1 |
| Fokkens, WJ | 1 |
| Todd, DC | 1 |
| Kupczyk, M | 1 |
| Bogacka, E | 1 |
| Bocheńska-Marciniak, M | 1 |
| Sterchaluk-Grzyb, E | 1 |
| Tworek, D | 1 |
| Kuna, P | 1 |
| Siergiejko, Z | 1 |
| Michalska, I | 1 |
| Buko, Z | 1 |
| Swiderska, M | 1 |
| Chyrek-Borowska, S | 1 |
| Ekström, T | 1 |
| Osterman, K | 1 |
| Zetterström, O | 1 |
| Cieślewicz, G | 3 |
| Gondorowicz, K | 3 |
| Grzelewska-Rzymowska, I | 3 |
| Rozniecki, J | 3 |
| Labrecque, M | 1 |
| Ghezzo, H | 1 |
| L'Archevêque, J | 1 |
| Trudeau, C | 1 |
| Cartier, A | 1 |
| Malo, JL | 1 |
| Kroll, VM | 1 |
| Nothofer, B | 1 |
| Werdermann, K | 1 |
| Roquet, A | 1 |
| Dahlén, B | 1 |
| Kumlin, M | 1 |
| Ihre, E | 1 |
| Anstrén, G | 1 |
| Binks, S | 1 |
| Dahlén, SE | 1 |
| Corren, J | 1 |
| Harris, AG | 1 |
| Aaronson, D | 1 |
| Beaucher, W | 1 |
| Berkowitz, R | 1 |
| Bronsky, E | 1 |
| Chen, R | 1 |
| Chervinsky, P | 1 |
| Cohen, R | 1 |
| Fourre, J | 1 |
| Grossman, J | 1 |
| Meltzer, E | 1 |
| Pedinoff, A | 1 |
| Stricker, W | 1 |
| Wanderer, A | 1 |
| Pospelova, RA | 1 |
| Akimova, LG | 1 |
| Kolganova, NA | 1 |
| Zlatinskaia, GR | 1 |
| Reicin, A | 1 |
| White, R | 1 |
| Weinstein, SF | 1 |
| Finn, AF | 1 |
| Nguyen, H | 1 |
| Peszek, I | 1 |
| Geissler, L | 1 |
| Seidenberg, BC | 1 |
| de Longueville, M | 1 |
| Geha, RS | 1 |
| Meltzer, EO | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Papi, A | 1 |
| Papadopoulos, NG | 1 |
| Stanciu, LA | 1 |
| Degitz, K | 1 |
| Johnston, SL | 1 |
| Doggrell, SA | 1 |
| Wojciechowska, B | 2 |
| Town, GI | 1 |
| Dirksen, A | 1 |
| Engel, T | 1 |
| Frølund, L | 1 |
| Heinig, JH | 1 |
| Svendsen, UG | 1 |
| Weeke, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Airway Responses to Montelukast and Desloratadine.[NCT00424580] | 12 participants | Interventional | 2007-01-31 | Completed | |||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Validation Screening Protocol for the Diagnosis of Exercise-induced Bronchoconstriction in Young Elite Athletes (13-18 y)[NCT03587675] | 141 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
8 reviews available for loratadine and Asthma
| Article | Year |
|---|---|
[Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma].
Topics: Anti-Allergic Agents; Asthma; Forced Expiratory Volume; Humans; Loratadine; Peak Expiratory Flow Rat | 2011 |
Therapeutic points of intervention and clinical implications: role of desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Lo | 2002 |
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl | 2005 |
[Airway hyperreactivity and respiratory allergy in children].
Topics: Allergens; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Child; Ch | 1996 |
What are the candidate groups for pharmacotherapeutic intervention to prevent asthma?
Topics: Anti-Allergic Agents; Asthma; Cetirizine; Child; Clinical Trials as Topic; Cromolyn Sodium; Dermatit | 2000 |
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.
Topics: Asthma; Cholinergic Antagonists; Eosinophils; Histamine H1 Antagonists; Humans; Loratadine; Respirat | 2001 |
Triamcinolone: new and old indications.
Topics: Administration, Intranasal; Adult; Aerosols; Androstadienes; Anti-Inflammatory Agents; Arthritis, Rh | 2001 |
Are antihistamines useful in managing asthma?
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchospirometry; Cetirizine; Cyclopropa | 2002 |
27 trials available for loratadine and Asthma
| Article | Year |
|---|---|
Single-dose desloratadine and montelukast and allergen-induced late airway responses.
Topics: Acetates; Adult; Allergens; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Bronchial Provocati | 2009 |
Prevention of recurrent wheezing in young children by loratadine compared with ketotifen.
Topics: Administration, Oral; Anti-Allergic Agents; Asthma; Child, Preschool; Double-Blind Method; Female; H | 2009 |
A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Asthma; Beclomethasone; Chronic Disease; Cr | 2009 |
The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children.
Topics: Acetates; Adolescent; Age Factors; Asthma; Asthma, Exercise-Induced; Child; Cross-Over Studies; Cycl | 2002 |
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Female; Histamin | 2002 |
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
Topics: Acetates; Adenosine Monophosphate; Adult; Aged; Asthma; Bronchial Provocation Tests; Cetirizine; Cro | 2003 |
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm | 2003 |
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
Topics: Acetates; Adenosine Monophosphate; Adult; Asthma; Bronchial Hyperreactivity; Bronchial Provocation T | 2003 |
[Effects of H1 blocker and inhaled corticosteroids on asthmatic patients with allergic rhinitis].
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; | 2003 |
The bronchodilatory effects of loratadine, terbutaline, and both together versus placebo in childhood asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Asthma; Bronchodilator Agents; Child; | 2003 |
Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study.
Topics: Anti-Allergic Agents; Asthma; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Hist | 2004 |
Inflammatory basis of exercise-induced bronchoconstriction.
Topics: Acetates; Adolescent; Adult; Asthma; Bronchitis; Bronchoconstriction; Cross-Over Studies; Cyclopropa | 2005 |
Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.
Topics: Adult; Asthma; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Inflammation; Loratadine; Mal | 2005 |
Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen.
Topics: Acetates; Adult; Allergens; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Cross-Over S | 2005 |
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho | 2005 |
[The effect of loratadine on skin and bronchial reactivity and histamine liberation from basophils in patients with atopic asthma and allergic rhinitis].
Topics: Asthma; Basophils; Bronchial Provocation Tests; Histamine; Histamine Release; Humans; Loratadine; Rh | 1994 |
Lack of effect of loratadine on moderate to severe asthma.
Topics: Adolescent; Adult; Aged; Asthma; Bronchodilator Agents; Chemotherapy, Adjuvant; Cross-Over Studies; | 1995 |
[Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction].
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Drug Administration Schedule; Femal | 1995 |
Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine.
Topics: Administration, Inhalation; Adult; Aged; Asthma; Bronchoconstriction; Dose-Response Relationship, Dr | 1993 |
[Allergic bronchial asthma treated with Loratadine].
Topics: Adult; Asthma; Bronchial Hyperreactivity; Female; Humans; Loratadine; Lung Volume Measurements; Male | 1993 |
[Airway hyperreactivity and respiratory allergy in children].
Topics: Allergens; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Child; Ch | 1996 |
Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
Topics: Adolescent; Adult; Airway Obstruction; Allergens; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combi | 1997 |
[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee].
Topics: Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Asthma; Child, Pres | 1997 |
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E | 1997 |
Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
Topics: Acetates; Adolescent; Adult; Aged; Asthma; Chronic Disease; Cross-Over Studies; Cyclopropanes; Doubl | 2000 |
Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma.
Topics: Adult; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Cyproheptadine; Female; Histamine; H | 1990 |
Effect of a non-sedative antihistaminic (loratadine) in moderate asthma. A double-blind controlled clinical crossover-trial.
Topics: Adult; Asthma; Bronchi; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Female; Force | 1989 |
13 other studies available for loratadine and Asthma
| Article | Year |
|---|---|
Synthesis and antihistamine evaluations of novel loratadine analogues.
Topics: Animals; Anti-Allergic Agents; Asthma; Guinea Pigs; Histamine; Histamine Antagonists; Ileum; Loratad | 2011 |
Design, synthesis and antihistamine evaluations of several N-hydroxyalkyl desloratadine analogues.
Topics: Animals; Asthma; Chemistry Techniques, Synthetic; Drug Design; Female; Guinea Pigs; Histamine; Hista | 2012 |
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
Topics: Allergens; Animals; Asthma; Bronchial Hyperreactivity; Cytokines; Disease Models, Animal; Dose-Respo | 2003 |
[Respiratory allergies in the child and the adult].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag | 2004 |
[Combination therapy of allergic rhinitis. So that from hay fever asthma won't come].
Topics: Anti-Allergic Agents; Asthma; Child; Drug Therapy, Combination; Glucocorticoids; Histamine H1 Antago | 2004 |
[Claritin in the combined therapy of bronchial asthma].
Topics: Anti-Asthmatic Agents; Asthma; Drug Evaluation; Histamine H1 Antagonists; Humans; Loratadine; Remiss | 1997 |
Desloratadine: A new, nonsedating, oral antihistamine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Drug Interactions; Histamine H1 Antagonist | 2001 |
Desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; R | 2001 |
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.
Topics: Asthma; Bronchi; Epithelial Cells; HeLa Cells; Histamine H1 Antagonists; Humans; Intercellular Adhes | 2001 |
[The third-generation antihistaminics. Can they prevent the tier change?].
Topics: Asthma; Bronchial Hyperreactivity; Histamine H1 Antagonists; Humans; Loratadine; Placebos; Randomize | 2002 |
Desloratadine (Clarinex).
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Controlled Clinical Trials as Topic; Disorder | 2002 |
[Effect of loratadine--selective antagonist of histamine (H1) receptor--on allergen-induced bronchoconstriction in atopic asthmatics].
Topics: Adult; Animals; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Humans; Humic Subs | 1992 |
[Effect of loratadine (LO), a selective H1 antagonist, on histamine-induced bronchoconstriction].
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Histamine; Humans; Loratadi | 1992 |